期刊文献+

晚期胃癌姑息化疗与最佳支持治疗效果比较

下载PDF
导出
摘要 目的:比较晚期胃癌姑息化疗与最佳支持治疗的临床疗效。方法:晚期胃癌患者60例随机分为两组:(1)A组(化疗组):多西紫杉醇25mg/m2,静脉滴注1小时,第1、8、15天。奥沙利铂100mg/m2,静脉滴注2小时,第2天。每28天为1周期,至少完成2周期。期间予最佳支持治疗;(2)B组(支持组):单纯予以最佳支持治疗。结果:A组总生存期6.1个月,B组总生存期3.4个月。A组近期有效率30%,B组近期有效率0%。A组疼痛改善有效率43.3%,体重改善有效率16.7%。B组疼痛改善率0%,体重改善有效率6.7%。A组均优于B组,两组比较差异均有统计学意义(P<0.05)。结论:晚期胃癌姑息化疗对比最佳支持治疗可明显延长患者生存期,提高患者生活质量,毒性反应轻,耐受性好,值得临床推广。
出处 《交通医学》 2012年第4期345-346,共2页 Medical Journal of Communications
  • 相关文献

参考文献3

二级参考文献44

  • 1Ajani J.Clinical update on an international phase Ⅱ/Ⅲ docetaxel trial(TAX325)[C].Proc Update Meeting on GI C,2002.
  • 2Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multi-insti-tutional randomized trial of docetaxel plus cisplatin with or with out fluorouracil in patients with untreated,advanced gastric,or gastroesophageal[J].J Clin Oncol,2005,23(24):5660-5667.
  • 3Fulton B,Spencer CM.Docetaxel.A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer[J].Drugs,1996,51(6):1075-1092.
  • 4Bang YJ,KangWK,Kang YK,et al.Docetaxel 75mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:a phase II trial[J].Jpn J Clin Oncol,2002,32(7):248-254.
  • 5MaiM,Sakata Y,Kanamaru R,et al.A late phase II clinical study of RP56976(docetaxel) in patients with advanced or recurrent gastric cancer:a cooperative study group trial(group B)[J].Gan To Kagaku Ryoho,1999,26(4):487-496.
  • 6Yang L,Li LD,Chen YD.Estimate and prediction of mortality of malignant tumor in China in 2000 and 2005.Chin J Health Statistics (Chin) 2005; 22:218-231:.
  • 7Ajani JA,Fodor MB,Tjulandin SA,Moiseyenko VM,Chao Y,Cabral Filho S,et al.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma.J Clin Oncol 2005; 23:5660-5667.
  • 8Murad AM,Santiago FF,Petroianu A,Rocha PR,Rodrigues MA,Rausch M.Modified therapy with 5-fluorouracil,doxorubicin,and methotrexate in advanced gastric cancer.Cancer 1993; 72:37-41.
  • 9Dank M,Zaluski J,Barone C,Valvere V,Peschel C,Wenczl M,et al.Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in lst-line advanced gastric cancer patients.J Clin Oncol 2005; 23(16 suppl):4003.
  • 10Di Bartolomeo M,Buzzoni R,Mariani L,Ferrario E,Katia D,Gevorgyan A,et al.Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma.A randomized phase Ⅲ trial.Oncology 2006; 7 1:341-346.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部